Approval · Notice of Compliance 26544 · 2021
PERINDOPRIL/INDAPAMIDE: Notice of Compliance 26544
Issued August 30, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26544
- Date
- August 30, 2021
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Companies
- Canadian reference product
- COVERSYL PLUS HD (Servier Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PERINDOPRIL/INDAPAMIDE | 02519712 | Cancelled Pre Market |
| PERINDOPRIL/INDAPAMIDE | 02519720 | Marketed |
| PERINDOPRIL/INDAPAMIDE | 02519739 | Marketed |
Medicinal ingredients
- PERINDOPRIL ERBUMINE 2 MG per TAB
- INDAPAMIDE 0.625 MG per TAB
- PERINDOPRIL ERBUMINE 4 MG per TAB
- INDAPAMIDE 1.25 MG per TAB
- PERINDOPRIL ERBUMINE 8 MG per TAB
- INDAPAMIDE 2.5 MG per TAB